Search results for "fumarate"

showing 10 items of 97 documents

Effects of atypical antipsychotics on neurocognition in euthymic bipolar patients.

2011

Abstract Background Different factors may influence cognitive functioning in bipolar disorder such as the effect of subsyndromal symptoms, the history of psychotic symptomatology or substance abuse, negative symptomatology, chronicity, sleep disturbances, and hormonal factors. The effect of pharmacologic treatment on cognition is still uncertain because of an insufficient number of studies examining this issue. Objective The aims of this study were to compare neuropsychologic performance of treated bipolar patients with that of controls, including unmedicated patients and healthy subjects, as well as to evaluate possible neurocognitive differences among 3 different atypical antipsychotics. …

OlanzapineAdultMalemedicine.medical_specialtyDibenzothiazepinesBipolar DisorderAdolescentlcsh:RC435-571medicine.drug_classmedicine.medical_treatmentEmotionsAtypical antipsychoticNeuropsychological TestsYoung Mania Rating ScaleBenzodiazepinesExecutive FunctionQuetiapine FumarateYoung AdultCognitionMemorylcsh:PsychiatrymedicineHumansAttentionBipolar disorderPsychiatryAntipsychoticPsychiatric Status Rating ScalesRisperidoneCalifornia Verbal Learning TestMiddle Agedmedicine.diseaseRisperidonePsychiatry and Mental healthClinical PsychologyOlanzapineCase-Control StudiesQuetiapineFemalePsychologymedicine.drugClinical psychologyAntipsychotic AgentsComprehensive psychiatry
researchProduct

Regulation of tartrate metabolism by TtdR and relation to the DcuS–DcuR-regulated C4-dicarboxylate metabolism of Escherichia coli

2009

Escherichia coli catabolizes l-tartrate under anaerobic conditions to oxaloacetate by the use of l-tartrate/succinate antiporter TtdT and l-tartrate dehydratase TtdAB. Subsequently, l-malate is channelled into fumarate respiration and degraded to succinate by the use of fumarase FumB and fumarate reductase FrdABCD. The genes encoding the latter pathway (dcuB, fumB and frdABCD) are transcriptionally activated by the DcuS–DcuR two-component system. Expression of the l-tartrate-specific ttdABT operon encoding TtdAB and TtdT was stimulated by the LysR-type gene regulator TtdR in the presence of l- and meso-tartrate, and repressed by O2 and nitrate. Anaerobic expression required a functional fn…

OperonBiologymedicine.disease_causeMicrobiologyAntiportersSubstrate SpecificityOperonEscherichia colimedicinePromoter Regions GeneticTartratesEscherichia coliPsychological repressionHydro-LyasesRegulator geneNitratesEscherichia coli ProteinsPromoterGene Expression Regulation BacterialFumarate reductaseDNA-Binding ProteinsOxygenGlucoseBiochemistryDehydrataseFumaraseProtein KinasesTranscription FactorsMicrobiology
researchProduct

The cytoplasmic PASC domain of the sensor kinase DcuS of Escherichia coli : role in signal transduction, dimer formation, and DctA interaction

2013

The cytoplasmic PAS(C) domain of the fumarate responsive sensor kinase DcuS of Escherichia coli links the transmembrane to the kinase domain. PAS(C) is also required for interaction with the transporter DctA serving as a cosensor of DcuS. Earlier studies suggested that PAS(C) functions as a hinge and transmits the signal to the kinase. Reorganizing the PAS(C) dimer interaction and, independently, removal of DctA, converts DcuS to the constitutive ON state (active without fumarate stimulation). ON mutants were categorized with respect to these two biophysical interactions and the functional state of DcuS: type I-ON mutations grossly reorganize the homodimer, and decrease interaction with Dct…

PAS domainDicarboxylic Acid TransportersModels MolecularfumarateProtein ConformationEscherichia coli ProteinsDNA Mutational AnalysisDctAModels Biological570 Life sciencessignal transduction.Escherichia coliProtein Interaction Domains and MotifsProtein MultimerizationDcuS sensor kinaseProtein KinasesOriginal ResearchSignal Transduction570 Biowissenschaften
researchProduct

Expression of the succinate dehydrogenase genes (sdhCAB) from the facultatively anaerobic paenibacillus macerans during aerobic growth

1998

Paenibacillus (formerly Bacillus) macerans is capable of succinate oxidation under oxic conditions and fumarate reduction under anoxic conditions. The reactions are catalyzed by different enzymes, succinate dehydrogenase (Sdh) and fumarate reductase (Frd). The genes encoding Sdh (sdhCAB) were analyzed. The gene products of sdhA and sdhB were similar to the subunits of known Sdh and Frd enzymes. The hydrophobic subunit SdhC showed close sequence similarity to the class of Sdh/Frd enzymes containing diheme cytochrome b. From the sdhCAB gene cluster two transcripts were produced, one comprising sdhCAB, the other sdhAB. The transcripts were found only during aerobic growth, and the amount was d…

Paenibacillus maceranschemistry.chemical_classificationbiologySDHBSuccinate dehydrogenaseSDHAmacromolecular substancesGeneral MedicineFumarate reductasebiology.organism_classificationBiochemistryMicrobiologyPaenibacillusEnzymeBiochemistrychemistryGene clusterGeneticsbiology.proteinMolecular BiologyArchives of microbiology
researchProduct

Predicting Lung Deposition of Extrafine Inhaled Corticosteroid-Containing Fixed Combinations in Patients with Chronic Obstructive Pulmonary Disease U…

2021

Background: Functional respiratory imaging (FRI) is a computational fluid dynamics-based technique using three-dimensional models of human lungs and formulation profiles to simulate aerosol deposition. Methods: FRI was used to evaluate lung deposition of extrafine beclomethasone dipropionate (BDP)/formoterol fumarate (FF)/glycopyrronium bromide (GB) and extrafine BDP/FF delivered through pressurized metered dose inhalers and to compare results with reference gamma scintigraphy data. FRI combined high-resolution computed tomography scans of 20 patients with moderate-to-severe chronic obstructive pulmonary disease (mean forced expiratory volume in 1 second 42% predicted) with in silico comput…

PathologyRespiratory SystemPharmaceutical ScienceINHALATION030226 pharmacology & pharmacyPulmonary Disease Chronic Obstructive0302 clinical medicineAdrenal Cortex HormonesFormoterol FumaratePharmacology (medical)1102 Cardiorespiratory Medicine and Haematologycombination drugLungBRONCHODILATOROriginal Researchlung depositionBeclomethasonerespiratory systemDrug CombinationsTreatment OutcomeCorticosteroid1115 Pharmacology and Pharmaceutical SciencesPMDILife Sciences & BiomedicineCombination drugPulmonary and Respiratory Medicinemedicine.medical_specialtyLung depositionextrafinemedicine.drug_classIn silicoPulmonary diseaseSettore MED/10 - Malattie Dell'Apparato Respiratorioinhaled corticosteroid03 medical and health sciencespressurized metered-dose inhalerAdministration InhalationmedicineHumansIn patientComputer SimulationSMALL AIRWAYScombination drug extrafine functional respiratory imaging inhaled corticosteroid lung deposition pressurized metered-dose inhalerScience & TechnologyRespiratory imagingbusiness.industryDYSFUNCTION030228 respiratory systemASTHMAfunctional respiratory imagingbusiness
researchProduct

Functioning of DcuC as the C 4 -Dicarboxylate Carrier during Glucose Fermentation by Escherichia coli

1999

ABSTRACT The dcuC gene of Escherichia coli encodes an alternative C 4 -dicarboxylate carrier (DcuC) with low transport activity. The expression of dcuC was investigated. dcuC was expressed only under anaerobic conditions; nitrate and fumarate caused slight repression and stimulation of expression, respectively. Anaerobic induction depended mainly on the transcriptional regulator FNR. Fumarate stimulation was independent of the fumarate response regulator DcuR. The expression of dcuC was not significantly inhibited by glucose, assigning a role to DcuC during glucose fermentation. The inactivation of dcuC increased fumarate-succinate exchange and fumarate uptake by DcuA and DcuB, suggesting a…

Physiology and MetabolismMolecular Sequence DataMutantStimulationBiologymedicine.disease_causeMicrobiologyBacterial ProteinsFumaratesConsensus SequenceEscherichia colimedicineTranscriptional regulationDicarboxylic AcidsAnaerobiosisPromoter Regions GeneticMolecular BiologyEscherichia coliPsychological repressionDicarboxylic Acid TransportersBinding SitesBase SequenceEscherichia coli ProteinsSuccinatesGene Expression Regulation BacterialKineticsResponse regulatorGlucoseBiochemistryFermentationFermentationEffluxCarrier ProteinsRibosomesJournal of Bacteriology
researchProduct

Fumarate dependent protein composition under aerobic and anaerobic growth conditions in Escherichia coli

2020

Abstract In the absence of sugars, C4-dicarboxylates (C4DC) like fumarate represent important substrates for growth of Escherichia coli. Aerobically, C4DCs are oxidized to CO2 whereas anaerobically, C4DCs are used for fumarate respiration. In order to determine the impact of fumarate under aerobic and anaerobic conditions, proteomes of E. coli W3110 grown aerobically or anaerobically with fumarate and/or the non-C4DC substrate glycerol were comparatively profiled by nanoLC-MS/MS. Membrane enrichment allowed sensitive detection of membrane proteins. A total of 1657 proteins of which 646 and 374 were assigned to the cytosol or membrane, respectively, were covered. Presence of fumarate trigger…

Proteomics0301 basic medicineBiophysicsCatabolite repressionmedicine.disease_causeBiochemistryCarbon utilization03 medical and health sciencesFumaratesTandem Mass SpectrometryEscherichia colimedicineDicarboxylic AcidsAnaerobiosisEscherichia coli030102 biochemistry & molecular biologybiologyChemistryEscherichia coli ProteinsGene Expression Regulation BacterialAerobiosisDNA-Binding ProteinsCitric acid cycle030104 developmental biologyRegulonMembrane proteinBiochemistrycAMP receptor proteinbiology.proteinProtein KinasesAnaerobic exerciseTranscription FactorsJournal of Proteomics
researchProduct

Efficacy of a fixed combination of ciclesonide and formoterol: the EXCITED-study.

2011

SummaryRecommended treatment for moderate to severe asthma is the combination of an inhaled corticosteroid and a long-acting beta2-agonist. The present study was designed to evaluate the efficacy of a newly developed fixed combination of ciclesonide and formoterol in comparison to the marketed fixed combination of fluticasone and salmeterol in patients with moderate asthma.This was a phase II, multi-centre, randomized, parallel-group, double-blind, double-dummy study. After a 2-week run-in period, 160 patients with moderate asthma were randomized to a 6-week treatment with ciclesonide/formoterol 320/9 μg bid (CIC/F) or fluticasone propionate/salmeterol 250/50 μg bid (FP/S), both delivered a…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyAdolescentUrologyCiclesonideCiclesonideFluticasone propionatechemistry.chemical_compoundYoung AdultDouble-Blind Methodimmune system diseasesPregnenedionesForced Expiratory VolumeFormoterol FumarateGermanyAdministration InhalationmedicineHumansFixed combinationAlbuterolFormoterolAnti-Asthmatic AgentsChildGlucocorticoidsFluticasoneAgedFluticasone-Salmeterol Drug Combinationbusiness.industryrespiratory systemMiddle AgedAsthmaFluticasone-Salmeterol Drug Combinationrespiratory tract diseasesBronchodilator AgentsAndrostadienesDrug CombinationsTreatment OutcomeTolerabilitychemistryEthanolaminesAustriaFormoterol FumarateFemaleSalmeterolFormoterolbusinessmedicine.drugRespiratory medicine
researchProduct

Revising old principles of inhaled treatment in new fixed combinations for asthma.

2015

The major influencing factors on persistent asthma control are the selected treatment(s), the drug delivery route and patient's adherence to therapy, together with the influence of lifestyle (i.e. sedentary habit), comorbid conditions and specific asthma phenotypes. Inhaled corticosteroids (ICS) in combination with a long-acting β2-agonist (LABA) are the gold standard for management of persistent asthma, with maximal local targeting and minimal systemic side effects. Several innovative inhaler devices have been developed for effective local drug administration and good patient compliance to therapy. Recently, a new ICS/LABA fixed combination, formulated with fluticasone propionate (FP) and …

Pulmonary and Respiratory MedicineAdultmedicine.medical_specialtyDoseAdolescentmedicine.drug_classSettore MED/10 - Malattie Dell'Apparato RespiratorioFluticasone propionateFluticasone propionatelaw.inventionMedication AdherenceRandomized controlled triallawInternal medicineDrug CombinationFormoterol FumarateAdministration InhalationmedicineCorticosteroidAnti-Asthmatic AgentHumansPharmacology (medical)Anti-Asthmatic AgentsBronchodilator AgentAsthmabusiness.industryInhalerMedicine (all)Biochemistry (medical)medicine.diseaseAsthmaDiscontinuationInhaled treatmentBronchodilator AgentsDrug CombinationsAnesthesiaCorticosteroidFluticasoneFormoterol Fumaratebusinessmedicine.drugHumanPulmonary pharmacologytherapeutics
researchProduct

Fluticasone/formoterol combination therapy versus budesonide/formoterol for the treatment of asthma: a randomized, controlled, non-inferiority trial …

2012

The inhaled corticosteroid fluticasone propionate (fluticasone) and the long-acting β₂ agonist formoterol fumarate (formoterol) have been combined in a single aerosol inhaler fluticasone/formoterol (flutiform(®)). This study compared the efficacy and safety of fluticasone/formoterol with the combination product budesonide/formoterol (Symbicort(®) Turbohaler(®)).A randomized, double-blind, double-dummy, multicenter, Phase 3 study comprising a 7- (± 3) day screening, 2-4-week run-in, and 12-week treatment periods. Patients aged ≥ 12 years with moderate to severe persistent asthma for ≥ 6 months before screening and forced expiratory volume in one second (FEV₁) 50-80% predicted and ≥ 15% rever…

Pulmonary and Respiratory MedicineBudesonideAdultMaleAdolescentFluticasone propionateYoung AdultDouble-Blind Methodimmune system diseasesForced Expiratory VolumeFormoterol FumarateAdministration InhalationImmunology and AllergyMedicineHumansBudesonideFluticasoneAgedbusiness.industryInhalerDry Powder Inhalersrespiratory systemMiddle AgedAsthmarespiratory tract diseasesBronchodilator AgentsAndrostadienesDrug CombinationsBudesonide/formoterolEthanolaminesAnesthesiaPediatrics Perinatology and Child HealthSalbutamolFluticasoneFormoterol FumarateFemaleFormoterolbusinesshormones hormone substitutes and hormone antagonistscirculatory and respiratory physiologymedicine.drugThe Journal of asthma : official journal of the Association for the Care of Asthma
researchProduct